News
Article published in Clinical Pharmacology & Therapeutics on the evolution and future of Regulatory Sciences in the Netherlands
Regulatory sciences make medicines work! This is the conclusion of the recently published article in Clinical Pharmacology & Therapeutics (published online ahead of print). In the article, the Netherlands emerges as a vibrant hub for drug regulatory science, blending national expertise with international collaboration.
Authored by Marjon Pasmooij, Peter Mol, Sjaak Bot, and Bert Leufkens, "The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report," offers a comprehensive exploration of the factors driving the Netherlands' success in regulatory sciences. The full is available online here.
Three pivotal episodes that have shaped the trajectory of drug regulatory science in the Netherlands are highlighted in the article. First, the TI Pharma (which merged with CTMM to Lygature) Escher project, spanning from 2007 to 2012, served as a multistakeholder platform aimed at removing regulatory barriers in pharmaceutical R&D. This initiative not only stimulated research but also promoted innovative multistakeholder and multiperspective approaches to regulatory reform.
Secondly, the Dutch Medicines Evaluation Board (MEB) triggered a significant leap forward from 2012 to 2017 by investing in deeper interactions with academia and other stakeholders. By integrating regulatory sciences into its core functions, the MEB underscored the importance of regulatory science in enhancing the quality and efficiency of drug regulation.
Lastly, the establishment of the Regulatory Science Network Netherlands (RSNN) in 2015 marked a new era of multistakeholder engagement. The RSNN is a network organization driven by a collaboration between the MEB, industry organizations, academia and Lygature. Through open dialogue and transparency, the RSNN has addressed regulatory controversies and promoted innovative strategies, positioning the Netherlands as a leader in unbiased public innovation. Lygature's role in the RSNN consists of providing the necessary managerial and scientific expertise, ensuring inclusive discussions and meaningful outputs.
The article also underscores the dynamic evolution of legal frameworks in Europe, which have inspired relevant regulatory science questions. From orphan drug legislation to pharmacovigilance directives, these frameworks have shaped the research agenda and increased collaborations across disciplines.
Moreover, the pivotal role of clinical pharmacology in shaping regulatory science discussions is emphasized. By contributing to debates on clinical evidence requirements and innovative trial designs, clinical pharmacologists have played a central role in advancing regulatory science in the Netherlands.
Looking ahead, further advancements in regulatory science are anticipated, fueled by multidisciplinary collaborations and emerging technologies.
In summary, the article provides a comprehensive overview of the Netherlands' remarkable journey in drug regulatory science, underscoring the importance of collaboration, innovation, and transparency in shaping the future of drug regulation.
The full article is available online here: https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.3275